Why were mRNA vaccines earlier available than conventional vaccines?

The mRNA that is the basis for the vaccines can be produced quickly and efficiently in a laboratory. It is also relatively easy to modify to create more effective or targeted vaccines. In contrast, the production of the recombinant proteins used in other types of vaccines is elaborate and time consuming.

Moreover, the manufacturers had already achieved promising results with mRNA vaccines in the spring of 2020. These results underscored the potential of the vaccines and inspired a certain market confidence. This increased the financial possibilities of companies for the development of the vaccines.